ArticleJournal of perinatology : official journal of the California Perinatal Association2026
Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSignificant variability exists in the indications for and dosing of cryoprecipitate transfusions. We examined cryoprecipitate transfusions in neonates with a focus on indications, dosing, and the incidence of multi-donor exposure. STUDY
designIn this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected.
resultsIn total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved.
conclusionSignificant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.
Identifiers
42259950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.